BMS284756 is a novel des-F (6)-
Introduction
As a class, quinolone compounds have a wide therapeutic spectrum of activity against Gram-positive and -negative organisms; however, differences in potency among the marketed fluoroquinolones can occur. 1, 2 Although the newer fluoroquinolones generally have increased activity against Gram-positive and fastidious pathogens, they are no more active than ciprofloxacin and levofloxacin against many enteric and non-enteric Gram-negative species. 3 In previous studies, BMS284756 (formerly T-3811), a novel des-F (6)-quinolone, has shown good in vitro activity against methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, β-haemolytic Streptococcus spp. and Enterococcus faecalis. 4 BMS284756 was determined to have greater oral bioavailability compared with ciprofloxacin, 1 and was less toxic (both acute and chronic) than levofloxacin in animal models. 5, 6 The purpose of this study was to determine the in vitro activity of BMS284756 against bacterial bloodstream infection (BSI) isolates from the SENTRY antimicrobial surveillance programme. The potency and spectrum of BMS284756 were compared with that of other quinolones, including ciprofloxacin, gatifloxacin and levofloxacin.
Materials and methods

Bacterial isolates
A total of >10 000 bacterial BSI isolates were obtained from participant laboratories in North America (31 sites), Latin America (10 sites) and Europe (17 sites) from January to December 2000, as part of the SENTRY programme. 7 Likewise, the rank order of pathogens from Latin America was similar to previous years. 8 
Study design and susceptibility methods
The study protocol dictated that each medical centre collect the first 20 consecutive clinically significant BSI isolates (one per patient episode) per month and forward them to the reference laboratory (University of Iowa and JMI Laboratories, IA, USA) for susceptibility testing. Isolates were identified using the Vitek System (bioMérieux Inc., Hazelwood, MO, USA) supplemented with conventional tests as needed. Stock cultures of all isolates were kept at -80°C. All isolates were susceptibility tested, utilizing NCCLS reference broth microdilution methods, against a panel of antimicrobial agents, including BMS284756, ciprofloxacin, levofloxacin and gatifloxacin. 9,10 A colony suspension equal to a 0. 
Results
BMS284756 demonstrated good activity against the Grampositive cocci (Table 1) . Among the four quinolones tested, BMS284756 was the most active compound overall tested against oxacillin-susceptible and -resistant S. aureus (MIC 50 , ≥0.03 and 2 mg/L) and CoNS (MIC 50 , 2 and 1 mg/L), viridans group and β-haemolytic streptococci (MIC 50 0.06 mg/L) and S. pneumoniae (MIC 50 0.06 mg/L). None of the tested fluoroquinolones was very active against enterococci, with MIC 50 s of 0.5->4 mg/L and percentage susceptibility ranging from 40% (ciprofloxacin) to 76% (BMS284756). BMS284756 was the most active against vancomycin-resistant isolates with 46% inhibited at ≤4 mg/L. Using the proposed susceptibility breakpoint of ≤4 mg/L, 5 92->99% of the staphylococcal isolates, regardless of oxacillin susceptibility, were considered susceptible to BMS284756. The remaining quinolones had decreased activity against staphylococci (combined oxacillin-susceptible and -resistant populations) ranging in percentage susceptibility from 68% (ciprofloxacin) to 79% (gatifloxacin) for S. aureus, and 51% (ciprofloxacin) to 90% (gatifloxacin) for CoNS. In general, ciprofloxacin, levofloxacin and gatifloxacin were less active against oxacillin-resistant strains of Staphylococcus spp. than oxacillin-susceptible strains (Table 1 ).
Although the fluoroquinolones tested were very active against the viridans group streptococci (98-100% susceptible) and β-haemolytic streptococci (99-100%), BMS284756 was at least four-fold more potent than the other quinolones (MIC 90 0.12 versus 0.5-1 mg/L). Against S. pneumoniae, BMS284756 (MIC 90 0.06 mg/L) was eight-fold more potent than gatifloxacin (MIC 90 0.5 mg/L), 16-fold more potent than levofloxacin (MIC 90 1 mg/L) and 32-fold more potent than ciprofloxacin (MIC 90 2 mg/L). However, as seen with the other Streptococcus spp., levofloxacin (>99% of pneumococcal isolates susceptible), gatifloxacin (>99% susceptible) and BMS284756 (100% susceptible) were all very active against S. pneumoniae at their respective NCCLS breakpoint concentrations. [9] [10] [11] BMS284756 was generally two-to four-fold less potent than the other quinolones against Enterobacteriaceae, with MIC 90 s ranging from 0.5 mg/L (E. coli) to >4 mg/L (Serratia spp.), compared with ≤0.25-2 mg/L of the other three agents (Table 2 ). At the proposed or recommended NCCLS breakpoints, BMS284756 was comparable to the other agents against E. coli (92% susceptible versus 91-92%), Enterobacter spp. (91% versus 90-92%) and Klebsiella spp. (95% versus 93-95%), but was less active against Serratia spp. (88% versus 92-97%).
As a group, the four quinolones were only marginally active against P. aeruginosa (MIC 90 ≥ 4 mg/L; 71-74% susceptible) and Acinetobacter spp. (MIC 90 ≥ 2 mg/L; 45-55% susceptible). BMS284756 was the least active agent against BSI isolates of P. aeruginosa (MIC 50 2 mg/L; 71% susceptible) but was the most active drug against Acinetobacter spp. (MIC 50 4 mg/L; 55% susceptible). 
Discussion
Of the four quinolones tested, BMS284756 was the most potent and demonstrated the broadest spectrum of activity towards Gram-positive BSI isolates, confirming earlier results. 1,2,4-6 In contrast, BMS284756 was less potent against the Gram-negative enteric bacilli and P. aeruginosa BSI isolates. None of the quinolones tested showed significant activity against Enterococcus or Acinetobacter spp. However, given the potential breakpoint of ≤4 mg/L, excellent bioavailibility and other favourable pharmacokinetic parameters, BMS284756 may be a possible therapeutic alternative for infections due to a wide variety of pathogens, pending clinical trial results. 5
